Editas Medicine, Inc.
No SEC Form 4 filings for $EDIT in the last 30 days.
Editas Medicine (NASDAQ:EDIT) saw unusually heavy options activity Wednesday, with investors buying 2,160 call options, up about 245% versus average daily volume. Shares rose to $3.77 midday. The article also cites May 5 earnings: EPS of -$0.26 vs -$0.30 expected, revenue $2.83M vs $6.37M, and notes multiple analyst price targets.
Editas Medicine reported preclinical results for EDIT-401, an in vivo gene-editing system targeting the LDLR gene to lower LDL-C. In non-human primates, it showed about a 90% mean reduction in LDL-C and roughly 90% reductions in Lp(a) and ApoB, with correlated biomarker changes. GLP toxicology is ongoing with interim tolerability and no liver histopathology. The company plans an HeFH patient trial later this year and an IND filing after a successful FDA pre-IND meeting; shares fell on the news.
Editas Medicine Inc. (EDIT) reported a first-quarter loss of $25 million, or 26 cents per share, which exceeded Wall Street expectations. However, the genome editing company's revenue of $2.8 million for the period fell short of analysts' forecasts. This financial snapshot highlights Editas's mixed performance in its latest earnings report.
